A new publication dated September 1, 2026, describes a case of thyroid-stimulating hormone-secreting pituitary neuroendocrine tumor, known as TSH-PitNet, diagnosed during pregnancy. The case report appears in the Taiwanese Journal of Obstetrics & Gynecology and discusses treatment with a somatostatin analog, a drug class that includes lanreotide.
The publication is indexed under PubMed ID 42642161. As a case report, it documents a single clinical scenario involving diagnosis and management of this rare pituitary tumor type during pregnancy. The article title identifies the use of a somatostatin analog as part of the treatment approach described.
No additional details about the specific findings, outcomes, or treatment results were included in the event data provided. This brief reports only that the publication exists and its stated title, journal, and date. Readers interested in the clinical management approaches discussed in the case report should consult the full text directly through the journal or PubMed listing.
Lanreotide is an approved somatostatin analog used in various clinical contexts. This publication represents new literature relevant to the broader understanding of somatostatin analog use in complex clinical presentations. For general background on lanreotide, readers can refer to the compound overview for additional context.